AR054249A1 - Tratamiento de enfermedades del tejido conectivo de la piel - Google Patents

Tratamiento de enfermedades del tejido conectivo de la piel

Info

Publication number
AR054249A1
AR054249A1 AR20060101443A ARP060101443A AR054249A1 AR 054249 A1 AR054249 A1 AR 054249A1 AR 20060101443 A AR20060101443 A AR 20060101443A AR P060101443 A ARP060101443 A AR P060101443A AR 054249 A1 AR054249 A1 AR 054249A1
Authority
AR
Argentina
Prior art keywords
treatment
connective tissue
skin
tissue diseases
agonist
Prior art date
Application number
AR20060101443A
Other languages
English (en)
Spanish (es)
Inventor
Morten Sloth Weidner
Original Assignee
Astion Dev As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Dev As filed Critical Astion Dev As
Publication of AR054249A1 publication Critical patent/AR054249A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AR20060101443A 2005-04-13 2006-04-12 Tratamiento de enfermedades del tejido conectivo de la piel AR054249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200500529 2005-04-13

Publications (1)

Publication Number Publication Date
AR054249A1 true AR054249A1 (es) 2007-06-13

Family

ID=36703472

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101443A AR054249A1 (es) 2005-04-13 2006-04-12 Tratamiento de enfermedades del tejido conectivo de la piel

Country Status (28)

Country Link
US (4) US8426475B2 (enExample)
EP (1) EP1719507B1 (enExample)
JP (1) JP5021621B2 (enExample)
KR (1) KR101355422B1 (enExample)
CN (1) CN101203214B (enExample)
AR (1) AR054249A1 (enExample)
AT (1) ATE473735T1 (enExample)
AU (1) AU2006233502B2 (enExample)
BR (1) BRPI0609361A2 (enExample)
CA (1) CA2604758C (enExample)
CY (1) CY1111541T1 (enExample)
DE (1) DE602006015387D1 (enExample)
DK (1) DK1719507T3 (enExample)
EA (1) EA016082B1 (enExample)
ES (1) ES2348920T3 (enExample)
HR (1) HRP20100552T1 (enExample)
IL (1) IL186491A (enExample)
MX (1) MX2007012794A (enExample)
MY (1) MY147864A (enExample)
NO (1) NO331211B1 (enExample)
NZ (1) NZ562940A (enExample)
PL (1) PL1719507T3 (enExample)
PT (1) PT1719507E (enExample)
RS (1) RS51464B (enExample)
SI (1) SI1719507T1 (enExample)
TW (1) TWI366457B (enExample)
WO (1) WO2006108424A2 (enExample)
ZA (1) ZA200708748B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0604826D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders and pain
CA2656312C (en) 2006-07-10 2014-09-09 Intervet International B.V. Zilpaterol enantiomer compositions and methods of making and using such compositions
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
GB0805535D0 (en) * 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US20120252831A1 (en) * 2011-03-31 2012-10-04 Mustafa Nevzat Ilac Sanayii A.S. Compositions of opioid antagonists and methods for treating scleroderma therewith
CN102267917B (zh) * 2011-06-15 2013-07-31 浙江工业大学 一种盐酸甲氧那明的合成方法
EP2849577A1 (en) * 2012-05-18 2015-03-25 Intervet International B.V. A method of enhancing performance in broiler chickens
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
CN104606177B (zh) * 2014-11-21 2018-02-02 苏州君宁新药开发中心有限公司 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用
WO2018000098A1 (en) * 2016-06-30 2018-01-04 Cipher Pharmaceuticals Inc. Treatment of inflammatory myopathies
CN106580978A (zh) * 2016-11-30 2017-04-26 郑州仁宏医药科技有限公司 一种治疗皮炎的西药组合物及其应用
US10576043B2 (en) * 2017-08-10 2020-03-03 Avro Life Sciences, Inc. Transdermal drug delivery system
GB201714745D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
BR112021018481A2 (pt) * 2019-03-27 2021-11-23 Curasen Therapeutics Inc Agonista adrenérgico beta e métodos para usar o mesmo
CA3161376A1 (en) 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
CN112300237A (zh) * 2020-04-13 2021-02-02 苏州恩泰新材料科技有限公司 海豹胆酸的制备方法及其应用
KR20230084242A (ko) * 2020-10-09 2023-06-12 엠씨2 테라퓨틱스 리미티드 피부과적 병태의 치료
CN116236467B (zh) * 2023-02-07 2023-10-27 中国人民解放军总医院 西马特罗或其衍生物的新用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA7468B (en) 1973-01-16 1974-11-27 J Voorhees Compositions and treatment of proliferatave skin diseases with phosphodiesterase inhibitors
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
SU895445A1 (ru) * 1980-05-15 1982-01-07 Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова Способ лечени кожных форм красной волчанки
US4574129A (en) 1984-01-31 1986-03-04 Bristol-Myers Company Topical nonsteroidal anti-inflammatory methods
JPS61154201A (ja) 1984-12-26 1986-07-12 Matsushita Electric Ind Co Ltd 誘電体フイルタ
US4699777A (en) 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4980159A (en) 1989-05-23 1990-12-25 Bristol-Myers Squibb Company Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects
RU2092105C1 (ru) * 1989-11-20 1997-10-10 Нижегородский научно-исследовательский кожно-венерологический институт Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
JP2611073B2 (ja) 1990-07-26 1997-05-21 モンサント カンパニー 新規ポリアミンの製造方法
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
JP3294876B2 (ja) 1992-07-20 2002-06-24 トキコ株式会社 給油装置
WO1995019336A1 (de) 1994-01-12 1995-07-20 Iovis Biomedical And Pharmaceutical Consultants Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten
JPH07304647A (ja) 1994-05-09 1995-11-21 Kao Corp マッサージ用組成物
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
GB9510162D0 (en) * 1995-05-19 1995-07-12 Bouras Elias Compositions for the treatment of skin conditions
JPH09110674A (ja) 1995-10-16 1997-04-28 Kao Corp 浴用剤組成物
FR2740040B1 (fr) 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
AU737608B2 (en) * 1997-04-30 2001-08-23 Courage Corporation Pty Ltd Composition and methods using an eutomer
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2428753C (en) 2000-11-17 2013-05-21 Universita Degli Studi Di Cagliari Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
TWI334778B (en) 2001-12-03 2010-12-21 Wyeth Corp Inhibitors of cytosolic phospholipase a2
SI1496917T1 (sl) 2002-04-19 2006-06-30 Astion Dev As Kombinacija beta-2-adrenoceptorskih agonistov in aminosladkorjev in njihova uporaba za zdravljenje imonomodulatornih motenj
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US20040229849A1 (en) 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
HRP20050355A2 (en) * 2002-09-24 2005-10-31 Combinatorx Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NZ541234A (en) * 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
WO2004091540A2 (en) * 2003-04-15 2004-10-28 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
WO2005004852A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
TW200522932A (en) 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2005089741A2 (en) * 2004-03-17 2005-09-29 Sosei R&D Ltd. The treatment of inflammatory disorders and pain using beta-aminoalcohols
WO2005102296A2 (en) 2004-04-23 2005-11-03 Heptagen Limited Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
MX2007002742A (es) * 2004-09-07 2007-05-23 Sosei R & D Ltd Tratamiento de padecimientos inflamatorios y dolor.

Also Published As

Publication number Publication date
US20170157068A1 (en) 2017-06-08
PL1719507T3 (pl) 2010-12-31
IL186491A0 (en) 2008-08-07
MY147864A (en) 2013-01-31
KR101355422B1 (ko) 2014-02-06
ZA200708748B (en) 2010-03-31
TW200719882A (en) 2007-06-01
WO2006108424A2 (en) 2006-10-19
CA2604758A1 (en) 2006-10-19
CN101203214B (zh) 2012-11-21
JP5021621B2 (ja) 2012-09-12
CN101203214A (zh) 2008-06-18
CA2604758C (en) 2014-11-25
DK1719507T3 (da) 2010-11-01
SI1719507T1 (sl) 2010-11-30
AU2006233502A1 (en) 2006-10-19
JP2008535873A (ja) 2008-09-04
NZ562940A (en) 2010-02-26
HK1091739A1 (en) 2007-01-26
PT1719507E (pt) 2010-10-21
EA200702204A1 (ru) 2008-04-28
HRP20100552T1 (hr) 2010-11-30
EP1719507A1 (en) 2006-11-08
RS51464B (sr) 2011-04-30
ATE473735T1 (de) 2010-07-15
KR20080005957A (ko) 2008-01-15
TWI366457B (en) 2012-06-21
AU2006233502B2 (en) 2011-07-28
CY1111541T1 (el) 2015-08-05
US20060235048A1 (en) 2006-10-19
WO2006108424A9 (en) 2007-08-09
US8426475B2 (en) 2013-04-23
EP1719507B1 (en) 2010-07-14
US20130237607A1 (en) 2013-09-12
US9907765B2 (en) 2018-03-06
IL186491A (en) 2011-12-29
MX2007012794A (es) 2008-02-22
NO20075527L (no) 2008-01-14
NO331211B1 (no) 2011-10-31
US20190125699A1 (en) 2019-05-02
BRPI0609361A2 (pt) 2010-03-30
DE602006015387D1 (de) 2010-08-26
WO2006108424A3 (en) 2006-12-14
EA016082B1 (ru) 2012-02-28
ES2348920T3 (es) 2010-12-17

Similar Documents

Publication Publication Date Title
AR048705A1 (es) Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
ECSP24000004A (es) Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
MX2017016911A (es) Método para mejorar resultados en la salud.
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
ECSP077843A (es) Tratamiento o prevención del prurito
ES2421709T3 (es) Uso de veneno de abeja para tratar la enfermedad de Parkinson
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
EA200970562A1 (ru) Применение l-карнитина для получения лекарственного средства в форме глазных капель для лечения заболеваний роговицы
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
PE20080455A1 (es) Mirtazapina para el tratamiento de dolor neuropatico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal